Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 2/20 | 0.71 |
| ▸ | TLR2 | O60603 | 2/20 | 0.71 |
| ▸ | FBP1 | P09467 | 8/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 4/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.55 |
| ▸ | AHR | P35869 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509743 | 1.00 | TLR4 (0.71) | TLR4TLR2FBP1ALDH1A1LMNA | |
| SCHEMBL13515394 | 0.95 | TLR4 (0.66) | TLR4TLR2FBP1ALDH1A1LMNA | |
| SCHEMBL5688276 | 0.95 | TLR4 (0.66) | TLR4TLR2FBP1ALDH1A1LMNA | |
| SCHEMBL5688280 | 0.95 | TLR4 (0.66) | TLR4TLR2FBP1ALDH1A1LMNA | |
| SCHEMBL17070027 | 0.90 | FBP1 (0.64) | TLR4TLR2FBP1ALDH1A1LMNA | |
| SCHEMBL16632344 | 0.88 | PTGS2 (0.69) | TLR4TLR2FBP1ALDH1A1LMNA | |
| SCHEMBL16632342 | 0.88 | PTGS2 (0.69) | TLR4TLR2FBP1ALDH1A1LMNA | |
| SCHEMBL17070015 | 0.85 | FBP1 (0.62) | TLR4TLR2FBP1ALDH1A1LMNA | |
| SCHEMBL9827029 | 0.84 | PTGS2 (0.77) | TLR4TLR2FBP1ALDH1A1LMNA | |
| SCHEMBL9827026 | 0.84 | PTGS2 (0.77) | TLR4TLR2FBP1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637446-B2 | Fluorine-containing nitrile-oxide compound | DAIKIN INDUSTRIES, LTD. (JP) | 2017-05-02 | — | — | US | disclosed |
| US-20160002153-A1 | FLUORINE-CONTAINING NITRILE-OXIDE COMPOUND | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20150038545-A1 | HYDROXYPHENYL PYRROLE COMPOUNDS CONTAINING AN HYDROXAMIC ACID AS HDAC INHIBITORS AND MEDICINAL APPLICATIONS THEREOF | Universidad Del País Vasco (ES) | 2015-02-05 | — | — | US | disclosed |
| US-8841327-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| US-8841327-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| EP-1944303-B1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROCYCLE AND FUNGICIDE CONTAINING THE SAME | EISAI R&D MAN CO LTD (JP) | 2013-08-21 | — | — | EP | disclosed |
| US-8507530-B2 | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8507530-B2 | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| WO-2012136722-A1 | HYDROXYPHENYL PYRROLE COMPOUNDS CONTAINING AN HYDROXAMIC ACID AS HDAC INHIBITORS AND MEDICINAL APPLICATIONS THEREOF | IKERCHEM, S.L. (ES) | 2012-10-11 | — | — | WO | disclosed |
| EP-2508510-A1 | Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof | Ikerchem, S.L. (ES) | 2012-10-10 | — | — | EP | disclosed |
| EP-1944303-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROCYCLE AND FUNGICIDE CONTAINING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| WO-2008030520-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-0588785-A1 | UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-03-30 | — | — | EP | disclosed |
| US-5185363-A | Administering for treatment of inflammatory diseases | ABBOTT LABORATORIES (US) | 1993-02-09 | — | — | US | disclosed |
| EP-0588785-A4 | UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS. | ABBOTT LAB (US) | 1991-12-30 | — | — | EP | disclosed |
| WO-1990012008-A1 | UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1990-10-18 | — | — | WO | disclosed |
| EP-0292699-A2 | Urea based lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002153-A1 | FLUORINE-CONTAINING NITRILE-OXIDE COMPOUND | NOS1, AFF1, NOS2 | TLR4 3679/4885TLR2 3063/4885FBP1 2830/4885 |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | GPI, ERG28, MAN2A1 | TLR4 3571/4885TLR2 448/4885FBP1 426/4885 |
| US-20150038545-A1 | HYDROXYPHENYL PYRROLE COMPOUNDS CONTAINING AN HYDROXAMIC ACID AS HDAC INHIBITORS AND MEDICINAL APPLICATIONS THEREOF | HDAC1, HDAC5, HDAC2 | TLR4 1409/4885TLR2 2071/4885FBP1 861/4885 |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | GPR119, GPR55, GPR65 | TLR4 219/4885TLR2 243/4885FBP1 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.